These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 19153116)

  • 1. Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study.
    Bidard FC; Tournigand C; André T; Mabro M; Figer A; Cervantes A; Lledo G; Bengrine-Lefevre L; Maindrault-Goebel F; Louvet C; de Gramont A
    Ann Oncol; 2009 Jun; 20(6):1042-7. PubMed ID: 19153116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.
    Tournigand C; André T; Achille E; Lledo G; Flesh M; Mery-Mignard D; Quinaux E; Couteau C; Buyse M; Ganem G; Landi B; Colin P; Louvet C; de Gramont A
    J Clin Oncol; 2004 Jan; 22(2):229-37. PubMed ID: 14657227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG).
    Souglakos J; Androulakis N; Syrigos K; Polyzos A; Ziras N; Athanasiadis A; Kakolyris S; Tsousis S; Kouroussis Ch; Vamvakas L; Kalykaki A; Samonis G; Mavroudis D; Georgoulias V
    Br J Cancer; 2006 Mar; 94(6):798-805. PubMed ID: 16508637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116).
    Modest DP; Heinemann V; Schütt P; Angermeier S; Haberkorn M; Waidmann O; Graeven U; Wille K; Kunzmann V; Henze L; Constantin C; de Wit M; Denzlinger C; Ballhausen A; Kurreck A; Jelas I; Alig AHS; Stahler A; Stintzing S; Oettle H
    J Cancer Res Clin Oncol; 2024 Jul; 150(7):332. PubMed ID: 38951245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of FOLFIRINOX as second-line chemotherapy for metastatic pancreatic cancer after gemcitabine-based chemotherapy failure.
    Kobayashi N; Shimamura T; Tokuhisa M; Goto A; Endo I; Ichikawa Y
    Medicine (Baltimore); 2017 May; 96(19):e6769. PubMed ID: 28489753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741.
    Sanoff HK; Sargent DJ; Campbell ME; Morton RF; Fuchs CS; Ramanathan RK; Williamson SK; Findlay BP; Pitot HC; Goldberg RM
    J Clin Oncol; 2008 Dec; 26(35):5721-7. PubMed ID: 19001325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Evidence of FOLFIRI Combined with Anti-Angiogenesis Inhibitors or Anti-EGFR Antibodies for Patients with Early Recurrence Colorectal Cancer After Adjuvant FOLFOX/CAPOX Therapy: A Japanese Claims Database Study.
    Kagawa Y; Wang C; Piao Y; Jin L; Tanizawa Y; Cai Z; Sunakawa Y
    Target Oncol; 2024 Jul; 19(4):575-585. PubMed ID: 38691296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study.
    Tournigand C; André T; Achille E; Lledo G; Flesh M; Mery-Mignard D; Quinaux E; Couteau C; Buyse M; Ganem G; Landi B; Colin P; Louvet C; de Gramont A
    J Clin Oncol; 2023 Jul; 41(19):3469-3477. PubMed ID: 37379692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study).
    Mishima H; Oba K; Sakamoto J; Muro K; Yoshino T; Hyodo I; Maehara Y
    Jpn J Clin Oncol; 2012 Feb; 42(2):134-8. PubMed ID: 22167662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shifting to first-line regimen after previous failure of irinotecan and oxaliplatin containing chemotherapies in unresectable metastatic colorectal cancer: a retrospective study of case analysis.
    Hsu CW; King TM; Lin CH; Wang HT; Ou WC; Wang JH
    Int J Colorectal Dis; 2009 Apr; 24(4):377-83. PubMed ID: 19116722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy for metastatic colon cancer: No effect on survival when the dose is reduced due to side effects.
    Munker S; Gerken M; Fest P; Ott C; Schnoy E; Fichtner-Feigl S; Wiggermann P; Vogelhuber M; Herr W; Stroszczynski C; Schlitt HJ; Evert M; Reng M; Klinkhammer-Schalke M; Teufel A
    BMC Cancer; 2018 Apr; 18(1):455. PubMed ID: 29685155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic Significance of Surgical Margin Size After Neoadjuvant FOLFOX and/or FOLFIRI for Colorectal Liver Metastases.
    Miller CL; Taylor MS; Qadan M; Deshpande V; Worthington S; Smalley R; Collura C; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Parikh AR; Berger D; Tanabe KK; Lillemoe KD; Ferrone CR
    J Gastrointest Surg; 2017 Nov; 21(11):1831-1840. PubMed ID: 28884391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the second-line treatment efficacy in advanced gastric cancer patients previously treated with taxane-based triplet chemotherapy: a Turkish Oncology Group Study.
    Bir Yücel K; Uğraklı M; Sekmek S; Yıldırım N; Gürler F; Yazıcı O; Özet A; Bal Ö; Araz M; Artaç M; Özdemir N
    Curr Med Res Opin; 2024 Jul; 40(7):1137-1143. PubMed ID: 38857167
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials.
    Seligmann JF; Fisher D; Smith CG; Richman SD; Elliott F; Brown S; Adams R; Maughan T; Quirke P; Cheadle J; Seymour M; Middleton G
    Ann Oncol; 2017 Mar; 28(3):562-568. PubMed ID: 27993800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor Efficacy of Dual Blockade with Encorafenib + Cetuximab in Combination with Chemotherapy in Human BRAFV600E-Mutant Colorectal Cancer.
    Napolitano S; Woods M; Lee HM; De Falco V; Martini G; Della Corte CM; Martinelli E; Famiglietti V; Ciardiello D; Anderson A; Fowlkes NW; Villareal OE; Sorokin A; Kanikarla P; Coker O; Morris V; Altucci L; Tabernero J; Troiani T; Ciardiello F; Kopetz S
    Clin Cancer Res; 2023 Jun; 29(12):2299-2309. PubMed ID: 37040395
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOLFIRI-bevacizumab as a second-line treatment for advanced biliary tract cancer after gemcitabine-based chemotherapy.
    Roussot N; Vincent J; Palmier R; Constantin G; Bengrine L; Fumet JD; Ghiringhelli F
    Front Oncol; 2023; 13():1293670. PubMed ID: 38098503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of irinotecan, 5-fluorouracil and leucovorin for treatment in patients with previously untreated advanced colorectal cancer.
    Bae SB; Lee NS; Kim HJ; Kim KH; Kim HJ; Kim CK; Lee KT; Park SK; Won JH; Hong DS; Park HS
    Cancer Res Treat; 2006 Apr; 38(2):72-7. PubMed ID: 19771263
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble HLA-G expression levels and HLA-G/irinotecan association in metastatic colorectal cancer treated with irinotecan-based strategy.
    Scarabel L; Garziera M; Fortuna S; Asaro F; Toffoli G; Geremia S
    Sci Rep; 2020 May; 10(1):8773. PubMed ID: 32471996
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modified de Gramont with oxaliplatin in the first-line treatment of advanced colorectal cancer.
    Braun MS; Adab F; Bradley C; McAdam K; Thomas G; Wadd NJ; Rea D; Philips R; Twelves C; Bozzino J; MacMillan C; Saunders MP; Counsell R; Anderson H; McDonald A; Stewart J; Robinson A; Davies S; Richards FJ; Seymour MT
    Br J Cancer; 2003 Oct; 89(7):1155-8. PubMed ID: 14520437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
    Choi IS; Choi M; Lee JH; Kim JH; Suh KJ; Lee JY; Kang B; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
    PLoS One; 2018; 13(6):e0198544. PubMed ID: 29879177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.